Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance

Authors :: Seung Up Kim
Do Young Kim
S. Lee
Beom Kyung Kim
Jun Yong Park
Kwang Hyub Han
H. J. Ku
Kyu Sik Jung
Sang Hoon Ahn
Oidov Baatarkhuu
Source :: Journal of Viral Hepatitis. 24:141-147
Publication Year :: 2016
Publisher :: Wiley, 2016.
Abstract: Summary We compared the viral suppressive efficacy of tenofovir disoproxil fumarate (TDF) mono-rescue therapy (TDF group) and TDF plus entecavir (ETV) combination-rescue therapy (TDF + ETV group) in chronic hepatitis B (CHB) patients with lamivudine resistance and entecavir resistance. One hundred and thirty-three CHB patients with lamivudine and entecavir resistance were investigated. Ninety-six patients were treated with TDF and 37 with TDF + ETV for at least 6 months. We compared the virologic response rate (HBV DNA level

Full Text Access

Tools